Biotechnology and Modern Clinical Medicine: A Multidisciplinary Narrative Review Integrating Artificial Intelligence and Aging Research

Victor Junior Godinez Vazquez[1]

[1]Health Sciences Division (DCS), Master's in Clinical Research Program, University of Guanajuato, León, Guanajuato, Mexico

Publication Date 2026/01/16

Abstract

➢ *Background:*

The definition of biotechnology is undergoing rapid transformation in the 21st century. While traditionally confined to laboratory sciences and pharmaceutical development, biotechnology now extends into artificial intelligence, financial markets, and geopolitical strategy. This expansion creates conceptual confusion across clinical, research, and policy domains, particularly regarding the distinction between biosciences (the study of living organisms) and biotechnology (the application of living systems to solve problems).

➢ *Purpose:*

This narrative review clarifies the evolving scope of biotechnology and addresses knowledge gaps affecting clinicians, researchers, and policymakers. We integrate perspectives from clinical medicine, business strategy, and emerging technologies to provide a multidisciplinary foundation for understanding biotechnology's role in modern healthcare.

➢ *Methods:*

We synthesized recent data from the Stanford Emerging Technology Review (2025), National Science Foundation reports, National Academies publications, the US Director of National Intelligence Global Trends 2040 report, and multi-omics research indexed in PubMed (2015–2025). We analyzed biotechnology through clinical, economic, technological, and geopolitical lenses.

➢ *Key Findings:*

Four interconnected domains emerge: (1) convergence of artificial intelligence and biological systems in drug discovery; (2) multi-omics approaches enabling precision medicine and longevity interventions; (3) bioeconomic forces and geopolitical competition shaping innovation access; and (4) implications for clinical training and patient care.

➢ *Conclusions:*

Healthcare systems and clinicians cannot remain isolated from biotechnology's transformation. Understanding these multidisciplinary connections is essential for physicians navigating precision medicine, translational research, and evidence-based innovation.

Keywords: *Biotechnology; Artificial Intelligence; Precision Medicine; Aging Research; Longevity Science; Bioeconomy; Clinical Medicine.*

I. INTRODUCTION

Biotechnology, often described as the intersection of biology and technology, encompasses a wide range of scientific disciplines and applications aimed at developing innovative solutions for healthcare, agriculture, manufacturing, and environmental challenges. The field has undergone transformative advancements over the past two decades in genetic engineering, synthetic biology, and regenerative medicine, revolutionizing therapeutic approaches and significantly impacting medicine, public

health, and global economic systems. These advances have generated substantial economic transformations, enabling developers to access financing and financial markets, thereby driving revenue growth and creating new business cycles in the biomedical sector.

However, conceptual confusion persists regarding what biotechnology actually encompasses. According to Firdos (2020), a critical distinction must be made between biosciences and biotechnology. Bioscience is "the science that studies the basics and fundamentals of living organisms (bacteria or viruses), which include their structure and functions," allowing researchers to understand the internal organization and mechanisms of living systems. In contrast, biotechnology—or biotech—is "the application of the principles and practices of engineering and technology to the life sciences" (Firdos, 2020). While biosciences focus on understanding biological systems, biotechnology focuses on applying that understanding to solve practical problems.

The definition of biotechnology is undergoing rapid transformation as the field expands beyond traditional boundaries. The Stanford Emerging Technology Review (2025) proposes a comprehensive contemporary definition: "Biotechnology involves using living systems and organisms to develop or make products and solve problems." This broader conceptualization reflects biotechnology's expansion into artificial intelligence, financial markets, and geopolitical strategy—dimensions that extend far beyond laboratory sciences yet remain poorly integrated into clinical education despite their direct impact on patient care and healthcare systems.

For physicians, it is essential to recognize how these scientific and technological advances are reshaping patient care paradigms. The US Intelligence Community identifies both therapeutic benefits (personalized medicine, tissue engineering) and strategic risks (dual-use concerns, access disparities) in advanced biotechnology applications (Office of the Director of National Intelligence, 2021), underscoring that biotechnology has become a matter of national security, not merely clinical innovation. Healthcare systems—and the clinicians within them—cannot remain isolated from this transformation.

This review integrates multidisciplinary perspectives from clinical medicine, business strategy, and emerging technologies to provide a comprehensive foundation for understanding biotechnology's role in 21st-century healthcare. By examining the continuum from artificial intelligence applications to longevity science, we aim to equip clinician-researchers with the contextual knowledge necessary for engaging with precision medicine, translational research, and evidence-based innovation.

II. BIOTECHNOLOGY FUNDAMENTALS AND HISTORICAL EVOLUTION

➤ *Historical Development*
The development of biotechnology spans millennia, evolving through distinct phases that reflect humanity's increasing ability to manipulate living systems for practical purposes. The field's origins trace back thousands of years to what can be termed the "first generation" of biotechnology, marked by the beginning of agriculture and animal domestication. Ancient civilizations practiced selective breeding of seeds and plants to enhance desirable traits while domesticating animals for food production, labor, and materials. Fermentation processes, discovered independently across multiple cultures, enabled the production and preservation of foods such as bread, cheese, and alcoholic beverages, as well as the processing of materials like leather for clothing and footwear. These early biotechnology applications, though lacking scientific understanding of underlying mechanisms, demonstrated practical manipulation of biological processes (Firdos, 2020).


Fig 1 The Biotechnology Evolution

A vertical timeline illustrating the progression of biotechnology from ancient organic practices through molecular discovery and programmable medicine, highlighting the convergence of biological systems with digital precision.

The scientific foundations of modern biotechnology emerged gradually from the 17th through 19th centuries. The development of microscopy enabled visualization of microorganisms, while Louis Pasteur's work in the 1850s–1860s elucidated the role of microbes in fermentation and disease, establishing the germ theory of disease. Gregor Mendel's experiments with pea plants in the 1860s revealed fundamental principles of inheritance, though their significance was not recognized until the early 20th century.

The discovery of penicillin by Alexander Fleming in 1928 marked a pivotal moment in biotechnology history. Fleming observed that a mold contaminating a Petri dish inhibited the growth of Staphylococcus colonies, demonstrating that antimicrobial products could serve as powerful therapeutic agents and launching the antibiotic era that transformed medicine (Bifulco et al., 2025).

➢ *The Molecular Biology Revolution*

The "second generation" of biotechnology began in the mid-20th century with the elucidation of DNA structure by James Watson and Francis Crick in 1953. This breakthrough set the stage for the recombinant DNA revolution and led directly to the founding of Genentech in 1976, the first biotechnology company focused on commercializing recombinant DNA technology. In 1978, Genentech produced recombinant human insulin, demonstrating the commercial and therapeutic potential of genetic engineering (Bifulco et al., 2025).

The development of polymerase chain reaction (PCR) by Kary Mullis in 1983 provided a powerful tool for amplifying DNA sequences, accelerating research and enabling new diagnostic applications. The Human Genome Project (1990–2003) mapped the entire human genetic blueprint, providing unprecedented insights into human biology and disease mechanisms. The discovery and development of CRISPR-Cas9 gene editing technology, building on bacterial immune system mechanisms, enabled precise DNA manipulation. Most recently, the rapid development and deployment of mRNA vaccines during the COVID-19 pandemic in 2020–2021 demonstrated biotechnology's potential for responding to global health emergencies, validating decades of fundamental research in molecular biology and immunology (Stanford Emerging Technology Review, 2025).

➢ *Contemporary Biotechnology Landscape*

Today, biotechnology leadership is concentrated primarily in the United States and China, creating a geopolitical landscape characterized by both opportunities and equity challenges. The United States maintains leadership in research investment, regulatory infrastructure, and commercial development, while China has rapidly expanded capabilities in genomics, synthetic biology, and biomanufacturing. The US Intelligence Community identifies both therapeutic benefits and strategic risks in advanced biotechnology applications, underscoring the field's national security dimensions (Office of the Director of National Intelligence, 2021).

Biotechnology continues to drive innovation through technological and scientific advances that promise to reduce disease burden, address food security, decrease petrochemical dependence, improve cognitive health, and transform environmental sustainability. These advancements hold the potential to enhance human welfare substantially. However, they must be developed and deployed while addressing critical concerns regarding market access, regulatory frameworks, safety standards, and ethical implications. Balancing the protection of human dignity and biosecurity with the imperative for continued innovation represents a central challenge for biotechnology in health, agriculture, manufacturing, and cognitive sciences.

III.   DRUG DEVELOPMENT AND ECONOMIC CONSIDERATIONS

➢ *The Therapeutic Development Pathway*

The drug development cycle represents one of the most complex and economically significant applications of modern biotechnology. This process typically begins with basic science research aimed at understanding disease mechanisms and identifying potential therapeutic targets. Translational research then connects these fundamental discoveries to potential human applications. During the preclinical phase, researchers conduct extensive in vitro (test tube) and in vivo (animal model) studies to evaluate the biological activity, safety profile, and pharmacological properties of drug candidates. Concurrently, investigators develop manufacturing processes and conduct toxicology studies to assess potential adverse effects. These preclinical data compilations are submitted to regulatory agencies such as the US Food and Drug Administration (FDA) to obtain permission to initiate testing in human subjects.

If preclinical studies demonstrate sufficient promise, the drug candidate advances to clinical trials—a multi-phase process designed to systematically evaluate safety and efficacy in human populations. Phase 1 trials assess basic safety and dosing in small numbers of healthy volunteers or patients. Phase 2 trials evaluate efficacy and further characterize safety in larger patient populations with the target disease. Phase 3 trials compare the new treatment against standard care in hundreds to thousands of patients to demonstrate clinical benefit. Throughout clinical development, manufacturers continue refining production processes to enable large-scale commercial manufacturing while maintaining product quality and consistency. Only after successfully completing this extensive evaluation process can a drug receive regulatory approval for marketing and clinical use (National Academies of Sciences, Engineering, and Medicine, 2025a).

Fig 2 The Therapeutic Development Pathway in Modern Biotechnology.

Illustrating the 8-step drug discovery process, from target identification through regulatory approval. Each phase highlights key activities, emphasizing the complexity, duration (10-15 years), Manufacturing refinement occurs iteratively across preclinical and clinical stages.

➢ *Economic Barriers and Investment Challenges*

This rigorous development pathway presents substantial economic challenges that significantly impact biotechnology innovation. According to the National Academies of Sciences, Engineering, and Medicine (2025a), drug development requires an average investment of approximately $1.1 billion per new molecular entity and often spans a decade or more from initial discovery to market approval. The process carries considerable risk, with only approximately 1 in 10 drug candidates entering Phase 1 clinical trials ultimately meeting statutory standards for regulatory approval. This high attrition rate, combined with the extended development timeline and substantial capital requirements, makes pharmaceutical development one of the most risk-intensive commercial endeavors.

These financial barriers create significant difficulties for translating scientific discoveries into therapeutic products. Academic researchers and early-stage biotechnology companies face particular challenges in attracting the private investment necessary to advance promising discoveries through expensive preclinical and clinical development stages. Many potential therapies, particularly those addressing rare diseases or conditions affecting economically disadvantaged populations, struggle to secure funding despite scientific merit and potential clinical value.

The United States currently leads global investment in therapeutic development, accounting for a substantial majority of worldwide pharmaceutical research and development expenditure. However, questions persist regarding whether these investments align optimally with therapeutic need and public health priorities, or whether market incentives primarily drive development toward commercially attractive rather than medically essential innovations (National Academies of Sciences, Engineering, and Medicine, 2025a). This misalignment between investment patterns and therapeutic need represents a critical challenge for biotechnology's ability to address global health priorities effectively.

IV. BIOTECHNOLOGY APPLICATIONS AND ECONOMIC IMPACT

➢ *Industrial Applications and Sectors*

Biotechnology and artificial intelligence are converging to create technologically advanced industries, products, and services across multiple sectors. Modern biotechnology has evolved as a science with substantial potential for human welfare, spanning applications from food processing to human health and environmental protection. Industrial biotechnology encompasses sustainable processing and production of chemical products, materials, and fuels, while contributing to industrial sustainability in chemicals, pharmaceuticals, pulp and paper, textiles, energy, and materials sectors (National Center for Science and Engineering Statistics, 2022).

Medicine represents one of the major application areas for biotechnology, including the use of organisms for novel drug production and stem cell therapies for tissue regeneration. Agricultural biotechnology employs recombinant DNA technology to produce transgenic plants with desirable genetic traits, enhancing crop yields and resistance to environmental stresses. These diverse applications demonstrate biotechnology's broad potential to address challenges in health, food security, and environmental sustainability.

Global Investment and Economic Impact

The United States ranks first globally in biotechnology investment. Within the US biotech sector, pharmaceutical and medicine manufacturers represent the largest segment (73% of investment), followed by scientific research and development services (13%), computer and electronic products manufacturing (4%), miscellaneous manufacturing including medical equipment and supplies (2%), and the food industry (2%) (National Center for Science and Engineering Statistics, 2022).

Biotechnology innovations can generate substantial health and economic benefits. For example, biotechnology-enabled crops have potential to reduce global food insecurity, with consequent positive effects on national economic indicators and government capacity to invest in infrastructure and population health. In medical applications, more than 260 novel human therapeutics were marketed in the United States between 1980 and 2014, covering 230 disease indications. Many of these biotechnology-based medicines treat symptoms associated with chronic conditions, enabling patients to work productively and maintain quality of life (National Center for Science and Engineering Statistics, 2022).

➢ *Research and Development Infrastructure*

Biotechnology development occurs through two primary domains: scientific research and development (R&D) and knowledge- and technology-intensive (KTI) industries. Scientific R&D includes: (1) basic research—experimental or theoretical work to acquire new knowledge without specific application; (2) applied research—investigation directed toward specific practical objectives; and (3) experimental development—systematic work to produce new materials, products, devices, processes, systems, and services based on existing knowledge.

Knowledge- and technology-intensive industries perform and fund more than half of US business R&D. During the COVID-19 pandemic, KTI industries supported the public health response by supplying medical products, enabling the transition to remote work and online learning, and facilitating digital delivery of telehealth services. The value added by KTI industries increased in 2020 even as GDP declined, led by growth in medical instruments, pharmaceuticals, information technology services, software publishing, and computer and electronic products. These industries employ disproportionately more workers in STEM occupations and have high concentrations of foreign-born workers, primarily from India, China, the Philippines, Vietnam, and Mexico (National Center for Science and Engineering Statistics, 2022).

V. MULTI-OMICS, AGING, AND ARTIFICIAL INTELLIGENCE

➢ *Molecular Determinants of Aging*

Multi-omics approaches integrate data from transcriptomics, epigenomics, proteomics, and metabolomics to elucidate molecular profiles underlying complex traits shaped by gene-environment interactions. These methods show particular promise for studying the molecular and pathway-level determinants of human cognition and behavior (National Academies of Sciences, Engineering, and Medicine, 2025b). However, to date, no genetic modifications have been identified that causally enhance physical or cognitive performance in human populations; only correlational associations have been established. While future research will continue investigating genetic determinants influencing cognitive function and brain health, current evidence does not support the feasibility of genetic enhancement technologies.

Recent longitudinal research has revealed nonlinear patterns in the human aging process. Shen et al. (2024) conducted a comprehensive multi-omics study of 108 individuals aged 25–75 years over a median follow-up of 1.7 years. Through integrated analysis of transcriptomics, proteomics, metabolomics, lipidomics, clinical laboratory tests, cytokine profiles, and microbiome composition, the investigators identified periods of substantial molecular dysregulation occurring at two specific chronological ages: approximately 44 years and 60 years. These findings suggest that aging does not proceed uniformly but involves periods of dramatic molecular alterations at specific life stages, presenting potential targets for precision medicine interventions.

➢ *Artificial Intelligence in Biomedical Discovery*

AI agents are emerging as powerful tools for accelerating biomedical research through advanced capabilities in proactive information acquisition, hypothesis generation, and experimental design. These systems employ perception modules, reasoning capabilities, and tool integration to refine scientific evidence and generate testable hypotheses. The future of AI in biomedicine envisions multi-agent systems combining heterogeneous capabilities with domain-specific tools under supervision of specialized human experts. Human feedback integration remains essential for promoting appropriate agent behavior and maintaining system robustness (Gao et al., 2024).

Error management represents a critical consideration in complex AI systems. As biological systems exhibit inherent variability and measurement uncertainty, AI agents must appropriately handle errors to maintain reliability. Ensuring proper context utilization and specific agent behavior requires ongoing refinement through iterative human-AI collaboration. The integration of AI capabilities with aging research, exemplified by the nonlinear dynamics identified by Shen et al. (2024), represents a promising frontier for developing precision medicine approaches targeting age-related molecular dysregulation (Lyu et al., 2024).

➢ *Artificial Intelligence in Medical Education and Clinical Practice*

The rapid advancement of artificial intelligence technologies presents both opportunities and risks for

medical education and clinical practice. AI systems can enhance professional efficiency and support clinical decision-making; however, over-reliance on these tools may diminish clinicians' independent problem-solving and critical reasoning capabilities. The inherent variability in AI-generated responses and potential for inaccuracies currently limit the unsupervised use of AI as a primary knowledge source in healthcare settings.

Abdulnour et al. (2025) emphasize that critical thinking skills serve as essential safeguards against AI-related biases and errors, recommending structured educational frameworks for supervising AI interactions among medical trainees. Reinforcing critical thinking competencies in medical education can facilitate the responsible integration of AI tools with biotechnology applications, ensuring that clinicians maintain the analytical capabilities necessary to evaluate AI-assisted recommendations in precision medicine contexts. This educational imperative becomes increasingly important as AI systems are deployed across biotechnology domains, from drug discovery to molecular diagnostics and treatment selection.

VI. PRECISION MEDICINE AND THERAPEUTIC EVOLUTION

➤ *The Precision Medicine Paradigm in Oncology*
Precision medicine represents a fundamental shift in therapeutic approaches, moving from population-based treatment protocols to individualized strategies guided by molecular characterization. Precision medicine trials have revolutionized cancer treatment through innovative trial designs aimed at optimizing anticancer therapy based on comprehensive molecular profiling. These approaches employ tumor and cell-free DNA profiling, immune markers, proteomic analyses, and RNA sequencing to identify individual patient characteristics and match them with effective targeted treatments (Tsimberidou et al., 2020). This evolution exemplifies the broader transformation of medicine, progressing from empirical treatment regimens to molecularly targeted therapies selected based on actionable genomic alterations.

The implementation of precision oncology trials has accelerated the translation of molecular discoveries into clinical practice. By identifying biomarkers that predict treatment response, precision medicine enables selection of therapies most likely to benefit individual patients while avoiding ineffective interventions and their associated toxicities. This paradigm shift relies heavily on biotechnology platforms including next-generation sequencing, liquid biopsy technologies, and computational biology to characterize the molecular landscape of individual tumors and guide therapeutic decision-making (Tsimberidou et al., 2020).

➤ *Challenges and Opportunities in Precision Medicine*
The adoption of precision medicine highlights fundamental challenges related to individual biological variability and the complexity of disease mechanisms.

Novel computational biomarkers, integrated with machine learning algorithms, have the potential to support diagnosis and disease management by identifying subtle patterns in high-dimensional molecular data. These approaches enable more precise measurement of disease states, including temporal dynamics of biomarker expression that may inform optimal timing of therapeutic interventions. Advanced analytics can detect patterns across multi-omics datasets that would be imperceptible through conventional analysis, enabling identification of patient subgroups likely to respond to specific treatments.

However, significant challenges remain in translating precision medicine discoveries into widespread clinical implementation. The integration of multi-omics approaches extends precision medicine principles beyond oncology to age-related conditions and preventive healthcare. As demonstrated by Shen et al. (2024), comprehensive molecular profiling can identify periods of dramatic biological change during aging, creating opportunities for targeted interventions. Combining biotechnology-enabled molecular characterization with AI-driven data analysis enables precision approaches to healthy aging and age-related disease prevention (Lyu et al., 2024).

➤ *Precision Psychiatry*
The success of precision medicine approaches in oncology, as discussed in Section 6.1, has not been paralleled in psychiatry, highlighting a significant gap in mental health therapeutics. A fundamental reform in clinical methodology is needed to shift psychiatric practice toward biomarker-guided treatment selection and precision medicine frameworks. Such transformation is essential to address the substantial societal burden of mental disorders and accelerate drug discovery in this underserved therapeutic area.

To drive this transformation, increased public and private investment must be aligned with the societal impact of mental disorders. Regulatory agencies should adopt more flexible and biomarker-informed trial designs, as has occurred in oncology and other medical fields (Cevoli et al., 2025). The disparity between investment in cancer therapeutics and mental health drug development persists despite comparable or greater population-level burden from psychiatric conditions.

Advances in neuroscience and brain process research that have progressed over recent decades provide opportunities for developing novel neurobiotechnologies. These emerging tools may help bridge the translational gap between basic neuroscience discoveries and clinical psychiatric applications, enabling more targeted and effective interventions for mental health conditions. The integration of multi-omics approaches, neuroimaging biomarkers, and computational psychiatry methods represents a promising frontier for transforming mental healthcare through precision medicine principles.

Table 1 Precision Medicine Implementation—Oncology vs. Psychiatry

Dimension	Oncology	Psychiatry	Gap Analysis
Biomarker availability	Extensive (mutations, expression profiles)	Limited (no validated diagnostic biomarkers)	Critical gap
FDA-approved targeted therapies	>80	<5	Major gap
Companion diagnostics	Routine clinical use	Research stage only	Major gap
Clinical trial innovation	Basket trials, umbrella trials, adaptive designs	Traditional RCT designs predominate	Moderate gap
Investment level	High (commercially attractive)	Low (market challenges)	Critical gap
Regulatory flexibility	Accelerated pathways established	Traditional pathways	Moderate gap
Molecular understanding	Driver mutations well-characterized	Complex polygenic architecture	Fundamental challenge

Source: Adapted from Tsimberidou et al. (2020) and Cevoli et al. (2025)

➤ *Economic and Systemic Considerations*

The economic implications of precision medicine are substantial and complex. While targeted therapies often carry higher upfront costs than conventional treatments, the ability to identify patients most likely to benefit can improve outcomes and reduce expenditure on ineffective interventions. Precision diagnostics enable more efficient use of expensive therapeutics by directing them toward patients with actionable molecular alterations, potentially improving the cost-effectiveness of cancer care despite higher per-patient treatment costs.

However, ensuring that precision medicine development aligns with therapeutic need rather than purely market incentives remains a critical challenge (National Academies of Sciences, Engineering, and Medicine, 2025a). The concentration of precision medicine research in oncology reflects both the molecular tractability of cancer and its commercial attractiveness, while other diseases with substantial public health impact receive less attention. Additionally, disparities in access to molecular profiling technologies and targeted therapies create equity concerns, as precision medicine benefits may accrue primarily to patients in well-resourced healthcare systems. Addressing these challenges requires coordinated efforts across research funding, regulatory policy, and healthcare delivery systems to ensure that precision medicine advances serve broad public health objectives.


Fig 3 Chaotic Wave of Precision Medicine Challenges.

A central chaotic wave core encircled by four faceted barriers: biological variability (wave peaks), translational gaps (data ripples), clinical implementation (crashing troughs), and access disparities (dividing swirls). This form underscores the turbulent, multifaceted nature of hurdles in advancing precision medicine.

VII. CONCLUSION

➤ *Summary and Implications*

The medical and scientific evolution of the 21st century, driven by disruptive innovations and technological advances, has expanded the therapeutic options available to clinicians for treating complex diseases. The precision medicine paradigm represents a

fundamental shift toward therapeutics designed to act at the epigenetic and biomolecular level, enabling mechanistic understanding of disease processes and development of targeted interventions. This approach holds promise for alleviating chronic disease burden and extending healthy lifespan through interventions tailored to individual molecular profiles and disease mechanisms.

Biotechnology continues to drive innovation through scientific advances that promise to reduce disease burden, address food security, decrease petrochemical dependence, improve cognitive health, and transform human interactions with the environment. These advancements hold substantial potential to promote human welfare. However, realizing this potential requires addressing critical market, regulatory, safety, and ethical concerns that protect human dignity and autonomy while fostering continued innovation in health, agriculture, manufacturing, and cognitive sciences.

The geopolitical concentration of biotechnology leadership, primarily in the United States and China, creates both opportunities for collaborative innovation and challenges related to equitable access and strategic competition. For clinicians, researchers, and industry stakeholders, these dynamics have practical implications for patient access, regulatory harmonization, and the implementation of precision medicine globally.

The convergence of biotechnology, artificial intelligence, and precision medicine—spanning applications from molecular profiling to longevity interventions—represents a promising frontier for 21st-century healthcare. Neurobiotechnologies represent a promising frontier for innovation, leveraging convergent advances in biotechnology and artificial intelligence to address unmet needs in neurological and psychiatric medicine. As demonstrated throughout this review, biotechnology has evolved from a laboratory discipline into a multifaceted field influencing clinical practice, economic systems, and geopolitical strategy. For clinicians and researchers, understanding these multidisciplinary connections is essential for navigating the future of personalized medicine, translational research, and evidence-based innovation. The challenge ahead lies not merely in advancing technological capabilities, but in ensuring that biotechnology innovations serve equitable, ethical, and sustainable healthcare objectives that benefit human populations globally.

➢ *Limitations*

This review has several limitations that should be acknowledged. As a narrative review, the literature selection process was not systematic, potentially introducing selection bias in the sources examined. The broad multidisciplinary scope, while providing comprehensive context, necessarily limits the depth of analysis achievable for any single domain. Additionally, the rapidly evolving nature of biotechnology, artificial intelligence, and precision medicine means that some content may become outdated as new developments emerge. The review primarily draws upon sources from United States institutions and perspectives, which may limit generalizability to other healthcare systems and geopolitical contexts. Future systematic reviews focusing on specific domains discussed here—such as AI integration in clinical practice or multi-omics applications in aging research—would provide more rigorous evidence synthesis and quantitative assessment of the findings presented.


Fig 4 Final Integration of Concepts in Graphic form.

DECLARATIONS

REFERENCES

[1]. Abdulnour, R. E., Gin, B., & Boscardin, C. K. (2025). Educational strategies for clinical supervision of artificial intelligence use. *The New England Journal of Medicine*, *392*(8), 786–797. https://doi.org/10.1056/NEJMra2503232

[2]. Bifulco, M., Di Zazzo, E., Affinito, A., & Pagano, C. (2025). The relevance of the history of biotechnology for healthcare: Teaching students how biotechnology and medicine have been closely entwined during the past century highlights how both fields have inspired and driven each other. *EMBO Reports*, *26*(2), 303–306. https://doi.org/10.1038/s44319-024-00355-8

[3]. Cevoli, F., Manji, H. K., Miller, A. H., Penninx, B. W. J. H., Kas, M., Pariante, C., De Picker, L., Swieboda, P., & Leboyer, M. (2025). Implementing precision medicine in psychiatry. *JAMA Psychiatry*. Advance online publication. https://doi.org/10.1001/jamapsychiatry.2025.3562

[4]. Firdos, A. (2020). *Biotechnology Fundamentals* (3rd ed.). CRC Press.

[5]. Gao, S., Fang, A., Huang, Y., Giunchiglia, V., Noori, A., Schwarz, J. R., Ektefaie, Y., Kondic, J., & Zitnik, M. (2024). Empowering biomedical discovery with AI agents. *Cell*, *187*(22), 6125–6151. https://doi.org/10.1016/j.cell.2024.09.022

[6]. Lyu, Y. X., Fu, Q., Wilczok, D., Ying, K., King, A., Antebi, A., Vojta, A., Stolzing, A., Moskalev, A., Georgievskaya, A., Maier, A. B., Olsen, A., Groth, A., Simon, A. K., Brunet, A., Jamil, A., Kulaga, A., Bhatti, A., Yaden, B., Pedersen, B. K., & Bakula, D. (2024). Longevity biotechnology: Bridging AI, biomarkers, geroscience and clinical applications for healthy longevity. *Aging*, *16*(20), 12955–12976. https://doi.org/10.18632/aging.206135

[7]. National Academies of Sciences, Engineering, and Medicine. (2025a). *Aligning investments in therapeutic development with therapeutic need: Closing the gap*. National Academies Press. https://doi.org/10.17226/29157

[8]. National Academies of Sciences, Engineering, and Medicine. (2025b). *Elucidating molecular and pathway-level determinants of cognitive performance in humans through multiomics: Issue paper*. National Academies Press. https://doi.org/10.17226/29080

[9]. National Center for Science and Engineering Statistics. (2022). *Science and Engineering Indicators 2022: Production and trade of knowledge- and technology-intensive industries*. National Science Foundation. https://ncses.nsf.gov/pubs/nsb20226/enabling-technologies#biotechnology

[10]. Office of the Director of National Intelligence. (2021). *Global Trends 2040: A more contested world*. National Intelligence Council. https://www.dni.gov/files/ODNI/documents/assessments/GlobalTrends_2040.pdf

[11]. Shen, X., Wang, C., Zhou, X., Zhou, W., Hornburg, D., Wu, S., & Snyder, M. P. (2024). Nonlinear dynamics of multi-omics profiles during human aging. *Nature Aging*, *4*(11), 1619–1634. https://doi.org/10.1038/s43587-024-00692-2

[12]. Stanford Emerging Technology Review. (2025). *2025 Technology Report: Biotechnology and Synthetic Biology*. Stanford University. https://setr.stanford.edu/technology/biotechnology-synthetic-biology/2025

[13]. Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020). Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treatment Reviews*, *86*, 102019. https://doi.org/10.1016/j.ctrv.2020.102019